Overview

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Status:
Completed

Trial end date:
2020-05-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.